Literature DB >> 2274472

Methotrexate binding to human plasma proteins.

L Skibińska1, C Ramlau, J Załuski, B Olejniczak.   

Abstract

The percentage of methotrexate (MTX) binding to plasma protein was 50.4 +/- 1.9 in healthy subject, and 32.3 +/- 3.6 in patients with cancer (breast carcinoma in most cases). Drugs used in combination with MTX in therapy (vincristine, vinblastine, cyclophosphamide, 5-fluorouracil, prednisone) depress the MTX binding to albumins. MTX binds to two kinds of albumins binding sites, with different binding constants: K1 = 8.88 mM-1 and K2 = 1.76 mM-1.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2274472

Source DB:  PubMed          Journal:  Pol J Pharmacol Pharm        ISSN： 0301-0244


  5 in total

1.  An Inexpensive, In-House-Made, Microdialysis Device for Measuring Drug-Protein Binding.

Authors:  Zackary M Herbst; Sayaka Shibata; Erkang Fan; Michael H Gelb
Journal:  ACS Med Chem Lett       Date:  2017-09-28       Impact factor: 4.345

Review 2.  Breast cancer: insights in disease and influence of drug methotrexate.

Authors:  Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal:  RSC Med Chem       Date:  2020-05-28

3.  Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

Authors:  Kunihiro Suzuki; Kosuke Doki; Masato Homma; Hirofumi Tamaki; Satoko Hori; Hisakazu Ohtani; Yasufumi Sawada; Yukinao Kohda
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

4.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

5.  The Extension of the LeiCNS-PK3.0 Model in Combination with the "Handshake" Approach to Understand Brain Tumor Pathophysiology.

Authors:  Makoto Hirasawa; Mohammed A A Saleh; Elizabeth C M de Lange
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.